

## Molecular Study on Cytokine Gene Polymorphism among Cases of Psoriasis

Ahmad Settin \*, Hanaa A. Hassan \*\*, Rizk El-Baz \*, Tahai A. Hassan \*\*

\* Genetics Unit, Children Hospital, Mansoura University, Egypt

\*\*Zoology Department, Faculty of science, Mansoura University, Egypt

### Abstract

**Background:** Psoriasis is a chronic inflammatory skin disease that varies in age and mode of onset, severity, course, duration and clinical morphology from one individual to another.

**Objectives:** To check for the association of polymorphisms of cytokine genes with the susceptibility and severity of Psoriasis in cases from Egypt.

**Subjects:** 46 cases with Psoriasis in addition to 98 healthy unrelated controls. Cases were classified into aggressive or early onset Psoriasis (17 cases, 36.9%) and late onset Psoriasis (29 cases, 63.1%).

**Methods:** DNA was amplified using PCR-SSP for detection of polymorphisms related to TNF- $\alpha$ <sup>-308</sup> (G/A), IL-10<sup>-1082</sup> (G/A), IL-6<sup>-174</sup> (G/C) and (IL-1 receptor antagonist) IL-1Ra (VNTR).

**Results:** Total cases showed high significant frequency of homozygous IL-10<sup>-1082</sup> (G/G) (OR=3.9, P<0.05), TNF- $\alpha$ <sup>-308</sup> (G/G) (OR=3.7, P<0.05) and IL-6<sup>-174</sup> C/C (OR=6.7, P<0.001). Where as early and late onset cases showed high significant frequency of homozygous for IL-6<sup>-174</sup> (C/C) (P<0.05) only. On the other hand, combined heterozygosity for IL-6<sup>-174</sup> (G/C) with IL-10<sup>-1082</sup> (G/A) showed lowest significant frequency among all cases (P<0.05) and were considered low risk genotypes.

**Conclusions:** Cytokine gene polymorphisms may be used as a marker for Psoriasis susceptibility, and severity helping for early diagnosis.

**Keywords:** cytokine, gene, Psoriasis, IL6, IL-10, TNF- $\alpha$  Abbreviations

TNF; tumor necrosis factor, IL; interleukin, IL-1Ra; IL-1 receptor antagonist, PCR-SSP: polymerase chain reaction with sequence specific primers.

### Introduction

Psoriasis (OMIM 177900) is an ancient and universal inflammatory initially described at the beginning of medicine in the *Corpus Hippocraticum*. Hippocrates (460–377 BCE) used the term unknown, it appears to result from a combination of genetic and environmental factors. It is frequently inherited and passed from one generation to the next, but not following a classical autosomal mendelian profile. While it may have originally been confused with leprosy (*lepra*, “to scale”), it is generally easy to recognize psoriasis when it presents in one of three typical presentations: guttate, pustular, and plaque-stage. provides a clinical view of untreated chronic stationary plaques distributed on the lower back Approximately 2–3% of the population worldwide is afflicted by psoriasis (Kruger *et al.*,2001). The most

frequent extracutaneous medical problem associated with psoriasis (besides arthritis of small joints) is the inflammatory bowel disorder Crohn disease (Bhalero *et al.*, 1998). Psoriasis can begin at any age, although epidemiological studies demonstrate that it most commonly appears for the first time between the ages of 15 and 25 years (Henseler *et al.*, 1985). Psoriasis pathogenesis is the trafficking of the activated T cell into the skin which is mediated by the cutaneous lymphocyte antigen (CLA) on the migrating T cell, and adhesion molecules such as E-selectin on the endothelial cells. Activated T cells generated from psoriatic lesions secrete high concentrations of interleukin-2 (IL-2), tumor necrosis factor-alpha (TNF- $\alpha$ ) and interferon-gamma (IFN- $\gamma$ ) indicating a significant role of TH<sub>1</sub>-mediated

inflammatory processes in the psoriatic skin (Lowes *et al.*, 2004). Accordingly, significant elevated serum levels of TH<sub>1</sub>-derived cytokines such as IFN- $\gamma$ , TNF- $\alpha$ , IL-12 or IL-18 has been described by others (Segedi *et al.*, 2003; Arican *et al.*, 2005) suggesting a local as well as a systemic dysregulation of cytokines towards a TH<sub>1</sub> dominance in psoriatics. Circulating TNF- $\alpha$ , IFN- $\gamma$ , IL-10, IL-12 or IL-18 levels have been found to be significantly correlated with disease severity.

IL-10 is a type 2 cytokine with major impact on immunoregulation, since it inhibits type 1/proinflammatory cytokine formation. Therefore, we investigated its role in psoriasis. We found a relative deficiency in cutaneous IL-10 mRNA expression compared with other inflammatory dermatoses. Interestingly, patients during established antipsoriatic therapy showed higher IL-10 mRNA expression of peripheral blood mononuclear cells than patients before therapy. This suggested that IL-10 may have antipsoriatic capacity. Therefore, we performed a phase 2 pilot trial with subcutaneous IL-10 administration (8  $\mu$ g/kg/d) over 24 d in three patients. Clinical efficiency measured by objective and subjective parameters was found (Asadullah *et al.*, 1998). Tumor necrosis factor (TNF)- $\alpha$  may play an important role in the pathogenesis of psoriasis (Bonifait *et al.*, 1999; Bonifait *et al.*, 1994). Increased levels of this proinflammatory cytokine have been detected in blood and psoriatic lesions of patients with psoriasis vulgaris, whereas anti-TNF- $\alpha$  therapy has produced dramatic improvements (Bonifait *et al.*, 1994). As certain allelic variants of the TNF- $\alpha$  gene are associated with increased or decreased production of TNF- $\alpha$ , the disturbed cytokine balance may be under genetic control. Commonly described variants of polymorphisms in Caucasians consist of G to A transitions in the promoter region at positions -238 and -308, although there is considerable diversity in the distribution among different populations with psoriasis (Bonifait *et al.*, 1999). Moreover, variants of TNF- $\alpha$  polymorphisms may be associated with specific psoriasis subgroups defined by early and late onset of the disease (Bonifait *et al.*, 1999.) In northern

Polish population compared the frequency of TNF- $\alpha$  -238 and -308 promoter polymorphisms in patients with psoriasis vulgaris and in healthy controls.

IL-1ra is produced by monocytes and macrophages and is released into the systemic circulation in > 100-fold excess than either IL-1 $\alpha$  or IL-1 $\beta$  after lipopolysaccharide (LPS) stimulation in human volunteers (Dinarello, 1998). The synthesis of IL-1ra and IL-1 $\beta$  are differentially regulated at their own promoter sites. Although bacterial LPS stimulate the synthesis of both IL-1 $\beta$  and IL-1ra, other stimuli cause differential release of IL-1ra and IL-1 $\beta$ . The anti-inflammatory cytokines IL-4, IL-6, IL-10, and IL-13 inhibit the synthesis of IL-1 $\beta$ , yet they stimulate the synthesis of IL-1ra (Dinarello, 1997).

IL-6 may also have anti-inflammatory effects. It inhibits the expression and release of IL-1 and TNF from macrophages *in vitro* and endotoxin induced TNF production and neutrophil influx in the airways *in vivo* (Ulich *et al.*, 1991). In IL-6 transgenic mice there is a lymphocytic infiltration around airways associated with reduced airways responsiveness (Dicosmo *et al.*, 1994).

## Subjects and Methods

This work included a random sample of 46 cases presenting with generalized form of psoriasis recruited from the Department of Dermatology, Mansoura University, which is the main referral site in the Nile Delta Region of Egypt. Studied cases (46) included 14 men and 32 women.

Cases genotypes were compared to 98 healthy unrelated adult volunteers with negative family history of the disease from the same locality. These included 52 males and 46 females and their mean age was 44.9  $\pm$  6.7 years.

### DNA extraction and purification

After obtaining informed consent from all cases and controls, venous blood samples (3 ml) were collected on EDTA (ethylenediamine tetra acetate) containing tubes, DNA was extracted promptly using DNA extraction and purification kit (Gentra Systems, USA) according to manufacturer's

instructions and then stored at  $-20^{\circ}\text{C}$  till use.

### PCR amplification

Three single nucleotide polymorphisms (SNPs) were analyzed including promoter sites TNF- $\alpha$ <sup>-308</sup> (G/A), IL-10<sup>-1082</sup> (G/A) and IL-6<sup>-174</sup> (G/C) as well as IL-1Ra<sup>VNTR</sup> as previously described (Sargen *et al.*,2000; Cavet *et al.*,2001; Cavet *et al.*,1999; Wilkinson *et al.*,1999). For TNF- $\alpha$ , IL-6 and IL-10 SNPs identification, PCR with sequence-specific primers (PCR-SSP) in two reactions employing a common forward and 2 reverse primers was used, and for IL-1Ra VNTR polymorphism, a single PCR reaction employing a forward and a reverse primers was used (All primers, Taq polymerase, dNTP, and MgCl<sub>2</sub> were purchased from QiaGene (QiaGene, USA)). The assay was performed in Techne-Genius thermal-cycler (England). Briefly, 100-500 ng of genomic DNA was added to 25  $\mu\text{l}$  of reaction mixture containing 1  $\mu\text{M}$  of each common/specific primer, 200  $\mu\text{M}$  of each dNTP, and 1 U of Taq DNA polymerase. We were careful to have master mixes for multiple cases and also for different polymorphisms at the same sitting with confirmation of the negative amplification to obtain accurate subject genotyping.

### Detection of amplified products

The entire reaction volume plus 5  $\mu\text{l}$  of bromophenol blue track dye were loaded into 2% agarose gel (Boehringer Mannheim) containing ethidium bromide. Gels were electrophoresed for 20 minutes at 200 V, photographed under UV light (320 nm) and then scored for the presence or absence of an allele specific band. Figure (1) shows the amplified PCR products of TNF- $\alpha$ <sup>-308</sup> (G/A), IL-10<sup>-1082</sup> (G/A) and IL-6<sup>-174</sup> (G/C) compared to size marker whereas figure 2. shows amplified alleles of IL-1Ra VNTR region in intron 2 of the gene.

### Statistical analysis

Data were processed and analyzed using the Statistical Package of Social Science (SPSS, version 10.0). The frequency of studied allelic polymorphisms among cases was compared to that of controls describing number and percent of

each and tested for positive association using Fisher's exact test (modified Chi square test) and Odds ratio with a minimum level of significance of  $<0.05$ .

### Results

Analysis of IL-10<sup>-1082</sup> (G/A) polymorphism among cases compared to controls (table 1, fig.1), showed that homozygous form G/G was found significantly high in total cases (OR=3.9,  $P<0.05$ ) this was also noted in cases subgroup especially in moderate severity (OR=4,  $P<0.05$ ) and plaque psoriasis (OR=4.9,  $P<0.0001$ ). Analysis of IL-6<sup>-174</sup> (G/C) polymorphism (table 2, fig.2), showed that homozygous form C/C was found significantly high in total cases (OR=6.7,  $P<0.001$ ), while the heterozygous form G/C was found significantly lower among the same groups ( $P<0.05$ ).

Analysis of TNF- $\alpha$ <sup>-308</sup> (G→A) polymorphism (table 3, fig.3), showed that homozygous form G/G was found significantly high in total cases (OR=3.7,  $P<0.05$ ) and high significant of heterozygous G/A. Analysis of IL-1Ra VNTR polymorphism (table 4, fig.4), showed non significant for genotype and alleles.

Analysis of the frequency of combined phenotypes (table 5), showed that the combined genotypes including interaction between homozygosity for the IL-10<sup>-1082</sup> G/G and IL-1Ra VNTR A<sub>1</sub>/A<sub>1</sub> with higher significant frequency among cases compared to controls (13.4% vs 3.1%) (OR= 4.75). And including interaction between heterozygosity for the IL-6<sup>-174</sup>G/C and IL10<sup>-1082</sup>G/A with lower significant frequency among cases compared to controls (47.8%vs77.6%) and heterozygosity for IL-6<sup>-174</sup>G/C and TNF- $\alpha$ <sup>-308</sup>G/A with lower significant frequency among cases compared to controls (41%vs73.5%).

Interestingly, no significant difference was found in the frequencies of all studied alleles except for IL-6 that showed significant higher frequency for C alleles and lower frequency for G alleles.

**Table 1: Frequency of IL-10<sup>-1082</sup> (G/A) genotype and allelic polymorphisms among psoriasis cases compared to controls with their statistical significance.**

	Total n	Individual genotype			Individual allele	
		G/G n <sub>1</sub> ,(%)	G/A n <sub>1</sub> ,(%)	A/A n <sub>1</sub> ,(%)	G n <sub>2</sub> ,(%)	A n <sub>2</sub> ,(%)
Total cases	46	9,(20)	28,(61)	9,(20)	46,(50)	46,(50)
Control	98	5,(5.1)	85,(86.7)	8,(8.2)	95,(48.5)	101,(51.5)
O.R,(95%CI)		3.9,(1.2:12.7)*	0.5,(0.2:1.2)	2.5,(0.6:11.06)	1.3,(0.8:2.2)	0.8,(0.5:1.2)
Severity						
Moderate	36	8,(22.2)	26,(72.2)	2,(5.6)	42,(53)	30,(47)
O.R,(95%CI)		5.3(1.6:18)*	0.4(0.2:1)	0.7(0.1:3.2)	1.5(0.9:2.6)	0.7(0.4:1.4)
Severe	10	0(0)	9(90)	1,(10)	9,(45)	11,(55)
O.R,(95%CI)		0.8,(0.04:16)	1.4,(0.2:12)	1.3,(0.1:11)	0.9,(0.3:2.2)	1.2,(0.5:2.9)
TYPE						
Plaque	29	7,(24.2)	17,(58.6)	5,(17.2)	31,(53)	27,(47)
O.R,(95%CI)		2.2,(0.5:9.6)	0.1,(0.07:0.3)*	0.8,(0.2:4)	1.1,(0.6:2)	0.9,(0.5:1.6)
Guttate	17	5,(29)	11,(65)	1,(6)	21,(62)	13,(28)
O.R,(95%CI)		7.8,(2:31)*	0.3,(0.1:6)*	0.7,(0.1:6)	1.7,(0.8:3.6)	0.6,(0.3:1.2)
Age						
<30Y	17	3,(17.5)	10,(59)	4,(23.5)	16,(47)	18,(53)
O.R,(95%CI)		3,(0.7:13)	0.3(0.1:0.9)*	2.4(0.7:9)	1,(0.5:2)	1,(0.5:2)
>30Y	29	6,(21)	18,(62)	5,(17)	30,(52)	28,(48)
O.R,(95%CI)		4,(1.1:12)	0.3,(0.1:0.9)*	1.6,(0.5:5.2)	1.2,(0.7:2.1)	0.8,(0.5:1.5)

\*P<0.05 \*\*P<0.001 OR (95% CI) = Odds Ratio (95% Confidence Interval)

**Table 2: Frequency of IL-6<sup>-174</sup> (G/C) genotype and allelic polymorphisms among psoriasis cases compared to controls with their statistical significance.**

	Total N	Individual genotype			Individual allele	
		G/G n <sub>1</sub> ,(%)	G/C n <sub>1</sub> ,(%)	C/C n <sub>1</sub> ,(%)	G n <sub>2</sub> ,(%)	C n <sub>2</sub> ,(%)
Total cases	46	1,(2.2)	31,(67.4)	14,(30.4)	33,(36)	59,(64)
Control	98	5,(5.1)	87,(88.8)	6,(6.1)	97,(49.5)	99,(50.5)
O.R,(95%CI)		0.4,(0.1:3.6)	0.3,(0.1:0.7)*	6.7,(0.3:19)**	0.6,(0.3:1)*	1.8,(1.1:3)*
Severity						
Moderate	36	1,(3)	27,(75)	8,(22)	29,(40)	43,(60)
O.R,(95%CI)		0.5,(0.1:5)	0.4,(0.1:1)	4.4,(1.4:14)*	0.7,(0.4:1)	1.4,(0.8:2.5)
Severe	10	0,(0)	4,(40)	6,(60)	4,(20)	16,(80)
O.R,(95%CI)		0.8,(0.04:16)	0.08,(0.02:0.3)**	23,(5:104)**	0.3,(0.08:0.8)*	3.9,(1.3:12)*
TYPE						
Plaque	29	1,(3.4)	20,(69)	8,(27.6)	22,(38)	36,(62)
O.R,(95%CI)		0.7,(0.1:6)	0.3,(0.1:0.8)*	5.8,(1.8:18.6)*	0.6,(0.3:1.1)	1.6,(0.9:2.9)
Guttate	17	0,(0)	11,(65)	6,(35)	11,(32)	23,(68)
O.R,(95%CI)		0.5,(0.02:9)	0.2,(0.1:0.8)*	8.4,(2.3:30.5)*	0.5,(0.2:1.1)	2.05,(0.9:4.4)
Age						
<30Y	17	0,(0)	11,(65)	6,(35)	11,(32)	23,(68)
O.R,(95%CI)		0.5,(0.03:9.2)	0.2,(0.07:0.8)*	8.4,(2.3:30)**	0.5,(0.23:1.1)	2,(1:4.6)
>30Y	29	1(3.4)	20(69)	8(27.6)	22(38)	36(62)
O.R,(95%CI)		0.7((0.07:6)	0.3(0.1:0.8)*	6(0.3:1.1)**	0.6(0.3:1.1)	1.6(0.9:3)

\*P<0.05 \*\*P<0.001 OR(95% CI)= Odds Ratio (95% Confidence Interval)

Molecular Study on Cytokine Gene Polymorphism among.....

Table 3: Frequency of TNF- $\alpha$  <sup>-308</sup> (G/A) genotype and allelic polymorphisms among psoriasis cases compared to controls with their statistical significance.

	Individual genotype			Individual allele		
	Total n	G/G n <sub>1</sub> (%)	G/A n <sub>1</sub> (%)	A/A n <sub>1</sub> (%)	G n <sub>2</sub> (%)	A n <sub>2</sub> (%)
Total cases	46	9,(19.5)	28,(61)	9,(19.5)	46,(50)	46,(50)
Control	98	6,(6.1)	81,(82.7)	11,(11.2)	93,(47.4)	103,(52.6)
O.R,(95%CI)		3.7,(1.2:11)*	0.3,(0.2:0.7)*	1.9,(0.7:5)	1.1,(0.7:1.8)	1,(0.6:1.5)
Severity						
Moderate	36	8,(22)	22,(61)	6,(17)	38,(53)	34,(47)
O.R,(95%CI)		4.38,(1.4:18)*	0.3,(0.1:0.8)*	1.6,(0.5:4.6)	1.2,(0.7:2)	0.8,(0.5:1.4)
Severe	10	1,(10)	6,(60)	3,(30)	8,(40)	12,(60)
O.R,(95%CI)		1.7,(0.2:16)	0.3,(0.1:1.2)	3.4,(0.8:15)	0.7,(0.3:1.9)	1.4,(0.5:3.4)
TYPE						
Plaque	29	7,(24.2)	17,(58.6)	5,(17.2)	31,(53)	27,(47)
O.R,(95%CI)		4.9,(1.5:16)	0.3,(0.1:0.7)*	1.6,(0.5:5.2)*	1.3,(0.7:2.3)	0.8,(0.4:1.4)
Guttate	17	2,(11.8)	11,(64.7)	4,(23.5)	15,(44)	19,(56)
O.R,(95%CI)		2,(0.4:11)	0.5,(0.1:1.5)	2.4,(0.7:9)	0.9,(0.4:1.8)	1.1,(0.5:2.4)
Age						
<30Y	17	3,(17.5)	10,(59)	4,(23.5)	16,(47)	18,(53)
O.R,(95%CI)		3,(0.7:13)	0.3,(0.1:0.9)	2.4,(0.7:9)	1,(0.5:2)	1,(0.5:2)
>30Y	29	6,(21)	18,(62)	5,(17)	30,(52)	28,(84)
O.R,(95%CI)		4,(1.1:12)	0.3,(0.1:0.9)	1.6,(0.5:5.2)	1.2,(0.7:2.1)	0.8,(0.5:1.5)

\*P<0.05 \*\*P<0.001 OR (95% CI) = Odds Ratio (95% Confidence Interval)

Table 4: Frequency of IL-1Ra VNTR genotype and allelic polymorphisms among psoriasis cases compared to controls with their statistical significance.

	Total N	Individual genotype		Individual allele	
		A <sub>1</sub> /A <sub>1</sub> n <sub>1</sub> (%)	A <sub>1</sub> /A <sub>2</sub> N <sub>1</sub> (%)	A <sub>1</sub> n <sub>2</sub> (%)	A <sub>2</sub> n <sub>2</sub> (%)
Total cases	46	32,(69.6)	14,(30.4)	78,(85)	14,(15)
Control	98	57,(58)	41,(42)	155,(79)	41,(21)
O.R,(95%CI)		1.6,(0.8:3.5)	0.6,(0.3:1.3)	1.5,(0.6:2.9)	0.7,(0.3:1.3)
Severity					
Moderate	36	24,(67)	12,(33)	60,(83)	12,(17)
O.R,(95%CI)		1.4,(0.6:3)	0.7,(0.3:1.5)	1.3,(0.7:2.7)	0.8,(0.4:1.5)
Severe	10	8,(80)	2,(20)	18,(90)	2,(10)
O.R,(95%CI)		3,(0.6:14)	0.3,(0.1:1.7)	2.4,(0.5:11)	0.4,(0.1:1.9)
Type					
Plaque	29	19,(66)	10,(34)	48,(83)	10,(17)
O.R,(95%CI)		1.4,(0.6:3.2)	0.7,(0.3:1.7)	1.3,(0.6:3)	0.7,(0.3:1.6)
Guttate	17	13,(76.5)	4,(23.5)	30,(88.2)	4,(11.8)
O.R,(95%CI)		2.3,(0.7:7.7)	0.4,(0.1:1.4)	1.98,(0.7:5.95)	0.5,(0.2:1.5)
Age					
<30Y	17	13,(76.5)	4,(23.5)	30,(88)	4,(12)
O.R,(95%CI)		3.2,(0.7:7.7)	0.4,(0.1:1.4)	2,(0.7:6)	0.5,(0.2:1.6)
>30Y	29	19,(65.5)	10,(34.5)	48,(83)	10,(17)
O.R,(95%CI)		1.4,(0.6:3)	0.7,(0.3:1.7)	1.3,(0.6:2.7)	0.8,(0.4:2)

**Table (5): Frequency of combined genotypes of different cytokines among cases compared to controls with their statistical significance.**


	Cases n, (%)	Control n, (%)	P	OR,(95% CI)
G1	<u>22,(47.8)**</u>	76,(77.6)	<u>0.0005</u>	<u>0.27,(0.12-0.56)#</u>
G2	<u>19,(41)**</u>	72,(73.5)	<u>0.004</u>	<u>0.3,(0.12-0.5)#</u>
G3	9,(20)	34,(35)	0.07	0.5,(0.2-1.1)#
G4	<u>6,(13.04)*</u>	3,(3.1)	<u>0.03</u>	<u>4.8,(1.1-20)#</u>
G5	9(19.6)	32(32.6)	0.12	0.5(0.2-1.2)

G1: IL-6<sup>-174</sup>G/C and IL10<sup>-1082</sup>G/A  
 G2: IL-6<sup>-174</sup>G/C and TNF-α<sup>-308</sup>G/A  
 G3: IL-6<sup>-174</sup>G/C and IL-1Ra VNTR A<sub>1</sub>/A<sub>2</sub>  
 G4: IL-10<sup>-1082</sup>G/G and IL1Ra VNTR A1/A1  
 G5: TNF-α<sup>-308</sup>G/A and IL-1Ra VNTR A<sub>1</sub>/A<sub>2</sub>

Number of studied cases= 46.

Number of controls= 98.

#= Significant OR >1 with lower limit of 95% CI > 1 (risk genotype).



**Fig. (1, 2, 3)** show products of PCR amplification products for detection of polymorphisms related to cytokine genes, IL-10 -1082 (allele G above and A below), IL-6 at position -174 (allele G above and C below), TNF-α at position -308 (allele G above and A below) respectively. Positive amplification of one allele indicates homozygosity for that allele while positive amplification of both alleles indicates heterozygosity.

**Fig.( 4)** shows PCR amplification product for detection of IL-1Ra (VNTR ) polymorphism. Positive amplification of allele 1 alone indicates homozygosity A1A1 while amplification of both alleles 1 and 2 indicates heterozygosity A1A2

## Discussion

Psoriasis is a genetically heterogeneous disorder involved with multiple genetic and environmental interactions. Based on its genetic framework, disease severity and locations (e.g. nails, joints, and palmoplantar), may differ between individuals and populations (Burden *et al.*, 1998).

Once at the inflamed skin site, the activated T lymphocytes encounter the initiating antigen, and release T-helper type 1 cytokines, which play a central role in the phenotypic expression of psoriasis (Guenther *et al.*, 2002; Mehlis *et al.*, 2003).

In this study, certain cytokine gene polymorphisms were presented in a significant higher frequency among Egyptian psoriatic cases compared to controls. These genotypes included IL-6<sup>-174</sup> C/C, IL-10<sup>-1082</sup> G/G, and TNF- $\alpha$ <sup>-308</sup> G/G. The latter markers were particularly noted to be high among cases of the plaque type and cases with moderate severity of the disease. On the other hand, IL-6<sup>-174</sup> G/C and TNF- $\alpha$ <sup>-308</sup> G/A genotypes showed a significant lower frequency among psoriasis cases compared to controls. Regarding the allelic frequencies of studied cytokine genes, only IL-6<sup>-174</sup> C allele has shown significant higher frequency among cases in contrast to IL-6<sup>-174</sup> G allele that showed a significantly lower frequency compared to controls.

Although the serum levels of studied cytokine was not determined, it is expected that these cases mostly had lower levels of IL-6 and TNF- $\alpha$  with higher levels of IL-10 since the IL-6 C allele and TNF- $\alpha$  G alleles were found to be associated with a lower plasma level while the IL-10 G allele is associated with higher plasma levels (Bonifati *et al.*, 1994; Mussi *et al.*, 1997; Tuner *et al.*, 1997; Fishman *et al.*, 1998).

This is probably supported by the previous observation that high levels of IL-10 in skin lesions, synovial fluid and sera of patients with psoriasis has an influence on disease susceptibility in patients with psoriasis (Etehad *et al.*, 1994; Elkayam *et al.*, 2000; Kane *et al.*, 2004; Arican *et al.*, 2005). In addition, systemically administered TNF- $\alpha$  has also caused an improvement in some cases with psoriasis

(Creaven *et al.*, 1991; Takematsu *et al.*, 1994).

Other studies have also reported a decreased frequency of TNF  $\alpha$ -308A allele (Nedoszytko *et al.*, 2007), with a trend for increased frequency of G allele in early onset psoriasis (Arias *et al.*, 1997; Reich *et al.*, 1999). However, other investigators reported no difference in the distribution of TNF- $\alpha$  alleles from control subjects (Takematsu *et al.*, 1989; Tigaleno *et al.*, 1994; Craven *et al.*, 2001; Al-Heresh *et al.*, 2002).

Other studies among English population also showed that polymorphisms in the genes encoding for IL-10 were probably contributing to susceptibility to psoriasis (Mallon *et al.*, 2000). On the other hand, Kingo *et al.* (2003) demonstrated that the IL-10 haplotype has a role in determining severity and course of plaque type of psoriasis among Estonian population. Craven *et al.* (2001) who demonstrated that there is an increase in frequency of the heterozygous IL-10 (G/A) genotype, and a corresponding lower frequency of both G/G and A/A genotypes in the subset of patients with late onset psoriasis. The result is only of borderline statistical significance. Moreover, the trend is for a higher frequency of heterozygous (G/A) genotype in all groups (early onset and late onset psoriasis and controls). However, HoÈhler *et al.* (1997); Arias *et al.* (1997); Reich *et al.* (1999) who reported that no significant differences in the genotype distribution with respect to age of onset of psoriasis, gender, or between patients with early onset psoriasis and the controls population among cases from South Carolina with a borderline result in comparing patients with late onset psoriasis with controls. Cases with late onset psoriasis had a higher frequency of the heterozygous (G/A) genotype (corresponding to 'intermediate' production of IL-10) and lower frequencies of both G/G and A/A genotypes. Also, Chang *et al.* (2007) found that no significantly different allelic, genotypic and haplotypic in patients with PsA among Chinese cases from Taiwan.

An associations of IL-1Ra VNTR allele A2 was previously reported with a variety of epithelial-related chronic inflammatory diseases including alopecia areata, lichen sclerosis, systemic lupus erythematosus, ulcerative colitis and scleroderma areata (Tarlow *et al.* 1993; Clay *et al.*, 1994; Mansfield *et al.*, 1994). Tarlow *et al.* (1993) have found that the frequency of allele A2 was raised in the cohort with early-onset psoriasis ( $P=0.05$ ) compared with controls and significantly decreased in the late-onset cohort ( $P=0.02$ ) compared with controls among English population. In contrast, this study showed that there was no significant difference in the frequencies of all genotypes and alleles related to IL-1Ra VNTR polymorphism in Egyptian psoriasis cases compared to controls. These results are supported by study carried out by Chang *et al.* (2007) and Peddle *et al.* (2004) among Chinese cases in Taiwan and Newfoundland population from Canada respectively stating that the IL-1Ra genetic polymorphisms did not appear to be associated with susceptibility to PV and PsA.

We can concluded that cytokine gene polymorphisms especially related to IL-10, TNF- $\alpha$  and IL-6 genes can be considered genetic markers for disease susceptibility and/or severity with potential impact on family counseling and disease management.

### Conclusion

It has been concluded that cytokine gene polymorphisms especially related to IL-10, TNF- $\alpha$  and IL-6 genes can be considered genetic markers for disease susceptibility and/or severity with potential impact on family counseling and disease management.

### References

1. Al-Heresh AM, Proctor J, Jones S M, Dixey J, Cox B, Welsh K and McHugh N (2002): Tumour necrosis factor- $\alpha$  polymorphism and the HLA-Cw\*0602 allele in psoriatic arthritis. *Rheumatol.*, 41(5):525-530
2. Arias AI, Giles B, Eiermann TH, Sterry W and Pandey JP (1997): Tumor necrosis factor-alpha gene polymorphism in psoriasis. *Exp. Clin. Immunogenet.*, 14(2): 118-140.
3. Arican O, Aral M, Sasmaz S and Ciragil P (2005): Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity, *Mediators Inflamm.*, 24: 273-279.
4. Asadullah Khusru , Sterry Wolfram , Stephanek Katja , Jasulaitis Dominik, Leupold Mattias , Audring Heike , Volk Hans-Dieter, and Wolf-Dietrich (1998): IL-10 Is a Key Cytokine in Psoriasis. *J. Clin. Invest.* Volume 101(4):783-794.
5. Bhalerao J and Bowcock AM (1998): The genetics of psoriasis: a complex disorder of the skin and immune system. *Hum. Mol. Genet.*, 7:1537-1545.
6. Bonifati C and Ameglio F (1999): Cytokines in psoriasis. *Int. J. Dermatol.*, 38:241-51.
7. Bonifati C, Carducci M and Cordiali-Fei P (1994): Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients relationships with disease severity. *Clin. Exp. Dermatol.*, 19: 383-390.
8. Burden AD, Javed S and Bailey M (1998): Genetics of psoriasis: Paternal inheritance and a locus on chromosome 6p. *J. Invest. Dermatol.*, 110(6):958-960.
9. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH and Middleton PG (2001): Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. *Blood*, 98:1594-1600.
10. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM and Dickinson AM (1999): Recipient tumor necrosis factor and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host diseases severity in HLA-matched sibling bone marrow transplants. *Blood*, 94: 3941-3946.
11. Chang YT, Chou CT, Yu CW, Lin MW, Shiao YM, Chen CC, Huang CH, Lee DD, Liu HN, Wang WJ and Tsai SF (2007): Cytokine gene polymorphisms in Chinese patients with psoriasis. *Br. J. Dermatol.*, 156(5):899-905
12. Clay FE, Cork MJ and Tarlow JK (1994): Interleukin-1 receptor antagonist gene polymorphism association with lichen sclerosis. *Hum. Genet.*, 94: 407-10.
13. Craven N, Jackson C and Kirby B (2001): Cytokine gene polymorphisms in psoriasis. *Br. J. Dermatol.*, 144(4):849-902



14. **Creaven PJ and Stoll HL (1991):** Response to tumour necrosis factor in two cases of psoriasis. *J. Am. Acad. Dermatol.*, 24(5 Pt 1):735-741.
15. **DiCosmo BF, Geba GP and Picarella D (1994):** Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyper reactivity. *J. Clin. Invest.*, 94:2028-35.
16. **Dinarello CA (1997):** Induction of interleukin-1 and interleukin-1 receptor antagonist. *Semin. Oncol.*, 24(suppl):S9-81, S9-93.
17. **Döcke (1998):** IL-10 Is a Key Cytokine in Psoriasis. *J. Clin. Invest.* 101(4), 783-794.
18. **Elkayam O, Yaron I and Shirazi I (2000):** Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. *Rheumatol. Int.*, 19(3):101-106.
19. **Ettehadi P, Greaves MW and Wallace D (1994):** Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. *Clin. Exp. Immun.*, 96(1):146-197.
20. **Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S and Woo P (1998):** The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *J. Clin. Invest.*, 1;102(7):1369-76.
21. **Guenther LC and Ortonne JP (2002):** Pathophysiology of psoriasis: science behind therapy. *J. Cutan. Med. Surg.*, 6(3 Suppl):2-7.
22. **Henseler T and Christophers E (1985):** Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. *J. Am. Acad. Dermatol.*, 13:450-456.
23. **Höhler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, Meyer zum Büschenfelde KH and Märker-Hermann E (1997):** A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. *J. Invest. Dermatol.*, 109(4):562-5.
24. **Kane D, Gogarty M and O'Leary J (2004):** Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. *Arthritis Rheumatol.*, 50(10):3286-3295
25. **Krueger G (2001):** The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. *Arch. Dermatol.*, 137:280-284.
26. **Kingo K, Koks S, Silm H and Vasar E (2003):** IL-10 promoter polymorphisms influence disease severity and course in psoriasis. *Genes. Immun.*, 4(6):455-461.
27. **Lowes M A, Lew W and Krueger J G (2004):** Current concepts in the immunopathogenesis of psoriasis. *Dermatol. Clin.*, 22: 349-369.
28. **Mallon E, Bunce M, Savoie H, Rowe A, Newson R, Gotch F and Bunker CB (2002):** HLA-C and guttate psoriasis. *Br. J. Dermatol.*, 143(6):1177-1182.
29. **Mansfield JC, Holden H and Tarlow JK (1994):** Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. *Gastroenterol.*, 43(1):33-42.
30. **Mehlis SL and Gordon KB (2003):** The immunology of psoriasis and biologic immunotherapy. *J. Am. Acad. Dermatol.*, 49(2):S44-50.
31. **Mussi A, Bonifati C and Carducci M (1997):** Serum TNF alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. *J. Biol. Regul. Homeost. Agents.*, 11(3):115-123
32. **Nedoszytko B, Szczerkowska-Dobosz A, Zablotna M, Gleń J, Rebała K, Roszkiewicz J (2007):** Associations of promoter region polymorphisms in the tumour necrosis factor- $\alpha$  gene and early-onset psoriasis vulgaris in a northern Polish population. *Br J. Dermatol.* 157(1):165-172.
33. **Peddle L, Butt C, Snelgrove T and Rahman P (2004):** Interleukin (IL) 1 $\alpha$ , IL1 $\beta$ , IL receptor antagonist, and IL10 polymorphisms in psoriatic arthritis. *Ann. Rheumatol. Dis.*, 64(7):1093-1097
34. **Reich K, Westphal G, Schulz T (1999):** Combined analysis of polymorphisms of the tumor necrosis factor- $\alpha$  and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. *J. Invest. Dermatol.*, 113: 214-234.
35. **Sargen K, Demaine AG and Kingsnorth AN (2000):** Cytokine gene polymorphisms in acute pancreatitis. *Pancreas*, 1:24-35.
36. **Segedi A, Aleksza M, Gonda A, Irinyi B, Sipka S, Hunyadi J and Antal-Szalmás P (2003):** Elevated rate of T-helper1 (T(H)1) lymphocytes and serum IFN-gamma levels in psoriatic patients. *Immunol. Lett.*, 86: 277-280.
37. **Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A and Duff GW (1993):** Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-

- bp tandem repeat. *Hum. Genet.*, 91(4):403-404.
38. Takematsu H, Ohta H and Tagami H (1989): Absence of tumour necrosis factor-alpha in suction blister fluids and stratum corneum from patients with psoriasis. *Arch. Dermatol. Res.*, 281: 398-400.
  39. Takematsu H, Takahashi K and Tagami H (1994): Systemic tumour necrosis factor (TNF) treatment in psoriasis. *Br. J. Dermatol.*, 124(2):209-219.
  40. Tigalnova M, Bjerke JR and Gallati H (1994): Serum levels of interferons and TNF-alpha are not correlated to psoriasis activity and therapy. *Acta. Dermatol. Venereol. Suppl.*, 186: 25-32.
  41. Turner DM, Williams DM and Sankaran D (1997): An investigation of polymorphism in the interleukin-10 gene. *Eur. J. Immunogenet.*, 24(1):1-8.
  42. Ulich TR, Yin S and Guo K (1991): Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. *Am. J. Pathol.*, 138:1097-101.
  43. Wilkinson R J, Patel P, Llewelyn M, Hirsch CS, Pasvol G, Snounou G, Davidson RN and Toossi (1999): Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1? on tuberculosis. *J. Exp. Med.*, 189: 1863-1874

## دراسة جزيئية على التباين الخاص لجين السيتوكين على حالات الصدفية في مصر

أحمد ستين\* ، هناء على حسن\*\* ، رزق الباز\* ، تحية على حسن\*\*

\* وحدة الوراثة- مستشفى الأطفال- جامعة المنصورة- مصر

\*\* قسم علم الحيوان- كلية العلوم- جامعة المنصورة- مصر

تهدف الدراسة الى القاء الضوء على الجينات التي تعتبر مهمة في مرض الصدفية مثل الانترلوكين-6 ومعامل موت الخلايا المبكر-الفا والانترلوكين-10 والانترلوكين-1 مضاد المستقبل وعلاقتها بالاستعداد للمرض وشدته. أوضحت هذه الدراسة أن هناك أشكال معينة في التركيب الجيني الوراثي للسيتوكينات موجودة بنسبه إحصائية معنوية في الحالات المرضية عنها في الأصحاء. اشتملت هذه التركيبات الجينية على التركيب الجيني المتجانس وراثياً للانترلوكين-10 (عند-1082) جوانين/جوانين والانترلوكين-6 (عند-174) سيتوزين/سيتوزين ومعامل موت الخلايا المبكر-ألفا (عند-308) جوانين/جوانين و التي يمكن أن تعتبر خطيرة وتعرض الأشخاص حاملها لتطور المرض. أيضاً أوضحت هذه الدراسة أن هناك أشكال معينة في التركيب الجيني للسيتوكينات موجودة بنسبة إحصائية معنوية منخفضة في الحالات المرضية عنها في الأصحاء. اشتملت هذه التركيبات الجينية على التركيب الجيني الغير متجانس وراثياً الانترلوكين-6 (عند-174) جوانين/سيتوزين ومعامل موت الخلايا المبكر-الفا(عند-308) جوانين/أدينين و التي يمكن أن تعتبر حماية ضد تطور المرض. علاوة على ذلك فان استخدام تقنية (SSP- PCR) تعتبر مهمة للتعرف على المرض و شدة خطورته.